Insights with Goldman Sachs Part 3: Regulatory dynamics and research trends
FDA had a record year for approvals in 2023 and continues to create regulatory pathways. The advice for biopharma: keep pushing regulatory boundaries. And drug development strategies should emphasize cross-pollination across therapeutic areas. Hear more from Amy McKee, MD, Chief Medical Officer and Global Head of Oncology Center of Excellence at Parexel.
Disclaimer: The views and opinions that the panelists express are their own and are for informational purposes only. They do not constitute a recommendation by Goldman Sachs Asset Management for you to take any action.